McLornan, Donal P;
Psaila, Bethan;
Ewing, Joanne;
Innes, Andrew;
Arami, Siamak;
Brady, Jessica;
Butt, Nauman M;
Cargo, Catherine;
Cross, Nicholas C. P;
Francis, Sebastian;
Frewin, Rebecca;
Garg, Mamta;
Godfrey, Anna L;
Green, Anna;
Khan, Alesia;
Knapper, Steve;
Lambert, Jonathan;
McGregor, Andrew;
McMullin, Mary Frances;
Nangalia, Jyoti;
Neelakantan, Pratap;
Woodley, Claire;
Mead, Adam;
Somervaille, Tim C. P;
Harrison, Claire N.
This document represents an update of the British Society for Haematology guideline on Myelofibrosis first published in 2012 and updated in 2015 These guidelines aim to pro-vide healthcare professionals with clear guidance on stratified management for primary myelofibrosis (PMF)...
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...
NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
Commercial arrangements
There is a simple discount patient access scheme for lenvatinib and a commercial access agreement for pembrolizumab. NHS organisations can g...
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to
improve quality of life and survival for adults with colorectal cancer through management of local
disease and secondary tumours (metastatic disease).
The recommendations in this guideline were developed befor...
The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandem...
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease)....
BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with meta...
This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life. A table of NHS England interim treatment regimens gives possible alter...
Dent, S;
Brezden-Masley, C;
Clarke, B;
Davis, MK;
Jassal, DS;
Johnson, C;
Lemieux, J;
Paterson, I;
Sebag, IA;
Simmons, C;
Sulpher, J;
Thain, K;
Thavendiranathan, P;
Wentzell, JR;
Wurtele, N;
Côté, MA;
Fine, NM;
Haddad, H;
Hayley, BD;
Hopkins, S;
Joy, AA;
Rayson, D;
Stadnick, E;
Straatman, L;
Virani, SA.
Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This ...
Antineoplásicos,
Biomarcadores,
Cardiotónicos,
Cardiotoxinas,
Troponina T,
Péptido Natriurético Encefálico,
Proteína C-Reactiva,
Antineoplásicos/efectos adversos,
Arritmias Cardíacas,
Cardiotoxicidad,
Trombosis Coronaria,
Diagnóstico Precoz,
Ecocardiografía Tridimensional,
Hipertensión/terapia,
Imagen por Resonancia Cinemagnética,
Isquemia Miocárdica,
Neoplasias/terapia,
Prevención Primaria,
Radioterapia,
Factores de Riesgo,
Disfunción Ventricular Izquierda,
Cardiotoxicidad/diagnóstico,
Cardiotoxinas/efectos adversos,
Radioterapia/efectos adversos
